Top
Leukemia-Blood Graft - Healing Genes
1390
post-template-default,single,single-post,postid-1390,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Leukemia-Blood Graft

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation

Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation


Phase 1

DESCRIPTION:

Researchers at University of Texas MD Anderson Cancer Center in Houston, TX are recruiting patients with leukemia (or other blood malignancies) to trial a new form of stem cell transplant where the stem cells are modified to remove certain types of cells that cause graft-versus-host disease.

Following chemotherapy and total body irradiation, the stem cells will be infused. Tacrolimus will be infused for about 2 weeks, then as a pill for at least 4 months; Filgrastim injected under the skin 1 time a day, to help with the growth of a type of healthy white blood cells that fight infection. Follow up continues up to 100 days after treatment.


PATIENT MUST:

  • Be 18 to 60 years of age
  • Lack an HLA matched related donor, lack of an immediately available 8/8 HLA matched unrelated donor
  • Have a malignancy meeting the study’s criteria for status and past treatment
  • Be HIV-negative

THE STUDY INVOLVES:

  1. Screening to confirm acceptance to the study.
  2. Admission to the hospital with chemotherapy to prepare the immune system.
  3. Total body irradiation.
  4. The engineered stem cells will be administered through an IV line.
  5. Follow up continues for ~100 days.

LOCATIONS & CONTACTS:
The study site is at the University of Texas MD Anderson Cancer Center in Houston, TX Map.

Contacts:
Stefan Ciurea, MD  |  713-792-8750  |  [email protected]
 
SPONSORS
M.D. Anderson Cancer Center
 
Or go online:
https://clinicaltrials.gov/show/NCT02960646

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader